Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CPBIO Holding Co's Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$332 Mil. Therefore, CPBIO Holding Co's EV-to-EBIT ratio for today is 7.90.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, CPBIO Holding Co's Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$405 Mil. Therefore, CPBIO Holding Co's EV-to-EBITDA ratio for today is 6.47.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, CPBIO Holding Co's Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$3,671 Mil. Therefore, CPBIO Holding Co's EV-to-Revenue ratio for today is 0.71.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
CPBIO Holding Co (HKSE:03839) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
CPBIO Holding Co's current Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$332 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
CPBIO Holding Co's current Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$405 Mil.
CPBIO Holding Co's current Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$3,671 Mil.
CPBIO Holding Co's current Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.
CPBIO Holding Co's current Enterprise Value is HK$2,621 Mil.
CPBIO Holding Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPBIO Holding Co Enterprise Value Related Terms
CPBIO Holding Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for CPBIO Holding Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
CPBIO Holding Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$2,621 Mil mean?
CPBIO Holding Co (HKSE:03839) has a Enterprise Value of HK$2,621 Mil as of Aug. 05, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CPBIO Holding Co and its competitors.
Is CPBIO Holding Co's Enterprise Value too high?
CPBIO Holding Co's current Enterprise Value is HK$2,621 Mil. Overall, CPBIO Holding Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Enterprise Value compare to ZTS?
CPBIO Holding Co's Enterprise Value of HK$2,621 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CPBIO Holding Co and its competitors. CPBIO Holding Co's current Enterprise Value is HK$2,621 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (HKSE:03839) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$4.36, compared to a current price of HK$9.20 — trading 110.9% above its estimated fair value. The current Enterprise Value is HK$2,621 Mil. CPBIO Holding Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For CPBIO Holding Co (HKSE:03839), the current Enterprise Value is HK$2,621 Mil as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of HK$9.20 is trading 110.9% above its estimated GF Value™ of HK$4.36.
GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.
Key valuation signals for HKSE:03839:
Enterprise Value: HK$2,621 Mil
GF Value™: HK$4.36 vs. price of HK$9.20 (110.9% above fair value)
No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score
Get the complete analysis for HKSE:03839
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03839 has been successfully added to your 
